Skip to main content
NASDAQ:NCTY

The9 Stock Forecast, Price & News

$15.28
-0.11 (-0.71 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.21
$15.37
50-Day Range
$13.44
$41.40
52-Week Range
$2.04
$89.20
Volume752,756 shs
Average Volume4.13 million shs
Market Capitalization$230.88 million
P/E RatioN/A
Dividend YieldN/A
Beta2
30 days | 90 days | 365 days | Advanced Chart
Receive NCTY News and Ratings via Email

Sign-up to receive the latest news and ratings for The9 and its competitors with MarketBeat's FREE daily newsletter.


The9 logo

About The9

The9 Limited, together with its subsidiaries, operates and develops online games in the People's Republic of China. The company offers online games, including multiplayer online games, mobile games, Web games, and TV games. It also develops mobile games, including CrossFire New Mobile Game and Audition; and provides technical consulting services. The company was formerly known as GameNow.net Limited and changed its name to The9 Limited in February 2004. The9 Limited was founded in 1999 and is headquartered in Shanghai, the People's Republic of China.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Business services, not elsewhere classified
Sub-IndustryN/A
Current SymbolNASDAQ:NCTY
CUSIPN/A
Phone86-21-5172-9999
Employees105
Year FoundedN/A

Sales & Book Value

Annual Sales$50,000.00
Book Value($58.14) per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap$230.88 million
Next Earnings DateN/A
OptionableOptionable

MarketRank

Overall MarketRank

0.52 out of 5 stars

Computer And Technology Sector

1101st out of 1,551 stocks

Business Services, Not Elsewhere Classified Industry

136th out of 191 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











The9 (NASDAQ:NCTY) Frequently Asked Questions

What stocks does MarketBeat like better than The9?

Wall Street analysts have given The9 a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but The9 wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting The9?

The9 saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 806,500 shares, an increase of 59.8% from the March 31st total of 504,600 shares. Based on an average trading volume of 2,770,000 shares, the days-to-cover ratio is currently 0.3 days. Approximately 7.1% of the company's stock are sold short.
View The9's Short Interest
.

How has The9's stock price been impacted by COVID-19?

The9's stock was trading at $6.3870 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NCTY stock has increased by 139.2% and is now trading at $15.28.
View which stocks have been most impacted by COVID-19
.

When did The9's stock split? How did The9's stock split work?

The9's stock reverse split before market open on Monday, October 19th 2020. The 1-10 reverse split was announced on Tuesday, October 13th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 16th 2020. An investor that had 100 shares of The9 stock prior to the reverse split would have 10 shares after the split.

Who are The9's key executives?

The9's management team includes the following people:
  • Mr. Jun Zhu, Co-Founder, Chairman & CEO (Age 54)
  • Mr. Chris Shen, Pres (Age 53)
  • Mr. Kwok Ho Lai, CFO & Director (Age 44)
  • Wendy Weng, Mang. of Investor Relations

Who are some of The9's key competitors?

What other stocks do shareholders of The9 own?

Based on aggregate information from My MarketBeat watchlists, some companies that other The9 investors own include Amarin (AMRN), Gevo (GEVO), Biocept (BIOC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), Acasti Pharma (ACST), Anavex Life Sciences (AVXL), BIOLASE (BIOL), EyePoint Pharmaceuticals (EYPT) and Jaguar Health (JAGX).

What is The9's stock symbol?

The9 trades on the NASDAQ under the ticker symbol "NCTY."

Who are The9's major shareholders?

The9's stock is owned by a variety of institutional and retail investors. Top institutional investors include Goldman Sachs Group Inc. (0.08%), Quantbot Technologies LP (0.03%) and UBS Group AG (0.01%).

Which institutional investors are buying The9 stock?

NCTY stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Quantbot Technologies LP, and UBS Group AG.

How do I buy shares of The9?

Shares of NCTY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is The9's stock price today?

One share of NCTY stock can currently be purchased for approximately $15.28.

How much money does The9 make?

The9 has a market capitalization of $230.88 million and generates $50,000.00 in revenue each year.

How many employees does The9 have?

The9 employs 105 workers across the globe.

What is The9's official website?

The official website for The9 is www.the9.com.

Where are The9's headquarters?

The9 is headquartered at BUILDING NO.3 690 BIBO ROAD ZHANG JIANG HI-TECH PARK, SHANGHAI F4, 201203.

How can I contact The9?

The9's mailing address is BUILDING NO.3 690 BIBO ROAD ZHANG JIANG HI-TECH PARK, SHANGHAI F4, 201203. The technology company can be reached via phone at 86-21-5172-9999 or via email at [email protected].com.


This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.